IP Verse

Treating Infections With Ceftolozane/Tazobactam In Subjects Having Impaired Renal Function - EP3043797

The patent EP3043797 was granted to Merck Sharp & Dohme on Apr 8, 2020. The application was originally filed on Sep 9, 2014 under application number EP14842042A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3043797

MERCK SHARP & DOHME
Application Number
EP14842042A
Filing Date
Sep 9, 2014
Status
Opposition Rejected
Nov 25, 2022
Publication Date
Apr 8, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBDec 21, 2020LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBB -

Patent Citations (2) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS2013065874
SEARCHUS2013065874

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- FIACCADORI et al., "Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation", Nephrology Dialysis Transplantation, (20060000), vol. 21, no. 5, pages 1402 - 1406, XP 055245160 [Y] 3-4, 7, 21 * ; especially pg 1403-1405 *
INTERNATIONAL-SEARCH-REPORT- HERSHBERGER et al., "Pharmacokinetics of CXA-101/tazobactam in subjects with mild or moderate renal impairment", 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/27th Intl. Congress of Chemotherapy (ICC), Milan, Italy, (20110507), XP008183516 [Y] 3-4, 7 * ; Abstract *
INTERNATIONAL-SEARCH-REPORT- MILLER et al., "CXA-201 (CXA/TAZ) Dose Selection Based on Probability of Target Attainment (PTA) and Drug Exposure in Subjects with Varying Degrees of Renal Impairment (RI", Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC);, Chicago, Illinois, (20110917), XP 055245156 [Y] 1-4, 7, 15, 17-18, 21
OPPOSITION- Anonymous, "Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function -Study Design, Data Analysis, and Impact on Dosing and Labeling", FDA Guidance, (19980300), pages 1 - 19, XP002744727
OPPOSITION- Anonymous, "Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis", NCT01345929, (20130822), pages 1 - 14, XP055981986
OPPOSITION- Anonymous, "Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections", NCT01445678, (20130820), pages 1 - 12, XP055981981
OPPOSITION- CHANDORKAR, G. et al., "723. Pharmacokinetics (PK) and Safety of Ceftolozane/Tazobactam (TOL/TAZ) in Subjects with Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD) on Hemodialysis (HD)", IDWeek, (20131004), page 1, XP055981950
OPPOSITION- CHANDORKAR, G. et al., "Pharmacothery", 2013 ACCP Annual Meeting, (20130000), vol. 33, no. 10, page e218, XP055981970
OPPOSITION- MILLER, B. et al., "Poster 1519: Pharmacokinetics (PK) of CXA-101/TAZOBACTAM(CXA/TAZ) in subjects with mild or moderate renal impairment", Joint Meeting of the European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy, Milan, Italy, (20110507), page 1, XP055981977
OPPOSITION- Zhanel George G., Chung Phillip, Adam Heather, Zelenitsky Sheryl, Denisuik Andrew, Schweizer Frank, Lagacé-Wiens Philippe R. S., Rubinstein Ethan, Gin Alfred S., Walkty Andrew, Hoban Daryl J., Lynch Joseph P., Karlowsky James A., "Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli", Drugs, (20140000), vol. 74, no. 1, pages 31 - 51, XP055981988
OPPOSITION- Patel N., Scheetz M. H., Drusano G. L., Lodise T. P., "Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success", J. Antimicrob. Chemother., (20100000), vol. 65, no. 11, pages 2285 - 2290, XP055981991
OPPOSITION- Wooley Myra, Miller Benjamin, Krishna Gopal, Hershberger Ellie, Chandorkar Gurudatt, "Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam", Antimicrob. Agents Chemother., (20140000), vol. 58, no. 4, pages 2249 - 2255, XP055352247
OPPOSITION- Mark Bounthavong, Donald Hsu, Mai-Chi Hong, "Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination", Infect. Drug Resist., (20130000), vol. 6, pages 215 - 223, XP055353028
SEARCH- B. Miller, "CXA-201 (CXA/TAZ) Dose Selection Based on Probability of Target Attainment (PTA) and Drug Exposure in Subjects with Varying Degrees of Renal Impairment (RI)", Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), (20110917), pages 1 - 2, URL: http://www.icaaconline.com/php/icaac2013abstracts/data/papers/2011/A/2011_A-1099.htm, (20160127), XP055245156 [I] 1-5,7-11 * the whole document * [Y] 6,12-14
SEARCH- HERSHBERGER E ET AL, "P1519 Pharmacokinetics of CXA-101/tazobactam in subjects with mild or moderate renal impairment", CLINICAL MICROBIOLOGY AND INFECTION, WILEY, (20110501), vol. 17, no. s4, ISSN 1469-0691, page s433, XP008183516 [Y] 1,2 * the whole document *
SEARCH- W. A. CRAIG ET AL, "In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum -Lactamases, in the Thighs of Neutropenic Mice", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (20130401), vol. 57, no. 4, doi:10.1128/AAC.01590-12, ISSN 0066-4804, pages 1577 - 1582, XP055116079 [Y] 1-14 * page 1581, column 2, paragraph 3 - page 1582, column 1, paragraph 2 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents